Advances in therapeutic strategies for Alzheimer's disease that lead to even small delays in
onset and progression of the condition would significantly reduce the global burden of the …

The diagnosis of Alzheimer's disease can be improved by the use of biological measures.
Biomarkers of functional impairment, neuronal loss, and protein deposition that can be …

We considered clinical observations in patients with obsessive–compulsive-and anxiety-
disorders, who underwent bilateral anterior capsulotomy, as well as anatomical and …

A new diagnostic indicator of FDG PET scan abnormality, based on age-adjusted t statistics
and an automated voxel-based procedure, is presented and validated in a large data set …

This multicenter study examined 18F-FDG PET measures in the differential diagnosis of
Alzheimer's disease (AD), frontotemporal dementia (FTD), and dementia with Lewy bodies …

Various biomarkers are available to support the diagnosis of neurodegenerative diseases in
clinical and research settings. Among the molecular imaging biomarkers, amyloid-PET …

Sixteen patients were studied by multitracer positron emission tomography (PET) within 6–
48 (mean of 23) h of onset of a hemispheric ischemic stroke and again 13–25 (mean of 15.6) …

Objective: To assess neurochemical deficits in patients with Parkinson disease (PD)
associated dementia (PDD) in vivo. Methods: The authors performed combined PET with N …

Objectives: To investigate whether the combination of fluoro-2-deoxy-d-glucose (FDG) PET
measures with the APOE genotype would improve prediction of the conversion from mild …

Background Subjects with amnesic mild cognitive impairment (aMCI) may include patients at
high risk for progression to Alzheimer disease (AD) and a population with different …